Skip to main content
AZN
NYSE Life Sciences

AstraZeneca CEO Pascal Soriot Buys £7.3M of Company Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$167.63
Mkt Cap
$257.666B
52W Low
$146.1
52W High
$212.71
52W Position info
15% above low
Off High info
21% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

AZN is trading near its 52-week low of $146.1 (15% above the low).

Summary

AstraZeneca's CEO bought £7.3M of company stock on the open market, a direct show of confidence from the top executive.


Key Events · Ownership and Investor Activity · AZN

  • CEO Buys £7.3M of Stock

    Pascal Soriot purchased 60,000 ordinary shares at GB£121.02 per share on 14 September 2026, totaling approximately GB£7.26M (~US$9.5M).

  • Open-Market Purchase, Not Compensation

    The transaction was a direct purchase on the London Stock Exchange, not an option exercise or performance award — indicating genuine personal conviction.

  • Follows Strong Pipeline News

    The purchase comes after a series of positive regulatory and clinical milestones in recent months, including FDA and EU approvals for multiple oncology assets.


Analysis · AZN · Life Sciences

CEO Pascal Soriot purchased 60,000 ordinary shares at GB£121.02 each on 14 September 2026, a total outlay of roughly GB£7.26 million (about US$9.5 million). This is a direct open-market purchase by the chief executive — real money out of pocket, not an option exercise or grant. For a company of AstraZeneca's size the dollar amount is modest, but CEO buying is a stronger conviction signal than any other insider action, and it comes amid a run of positive pipeline and regulatory news over the past three months.

How filings like this one have moved

In the 30 days to Sep 18, 2026, 29.2% of the 1713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AZN was trading at $167.63 on NYSE in the Life Sciences sector, with a market capitalization of approximately $257.7B. The 52-week trading range was $146.10 to $212.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AZN - Latest Insights

AZN
Sep 14, 2026, 7:36 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $162.77
Real-time Price: $167.63 info
Change: +$4.86 (+3%) info
Market Cap: $257.666B info
AZN
Sep 08, 2026, 9:04 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $163.95
Real-time Price: $167.63 info
Change: +$3.68 (+2%) info
Market Cap: $257.666B info
AZN
Sep 08, 2026, 6:29 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $161.61
Real-time Price: $167.63 info
Change: +$6.02 (+4%) info
Market Cap: $257.666B info
AZN
Sep 01, 2026, 7:27 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $162.17
Real-time Price: $167.63 info
Change: +$5.46 (+3%) info
Market Cap: $257.666B info
AZN
Sep 01, 2026, 7:10 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $161.46
Real-time Price: $167.63 info
Change: +$6.17 (+4%) info
Market Cap: $257.666B info